Lilly (Eli): Dawn score and attention ranking
Lilly (Eli) scores 35 out of 100 on the Dawn Index, built from 2 signals. It ranks #7 of 7 in Pharmaceuticals (S&P 500), #5 of 5 in Pharmaceuticals (Fortune 100), #56 of 57 in Health Care (S&P 500), #15 of 16 in Health Care (Fortune 100).
What drives the Lilly (Eli) Dawn score?
| Signal | Weight | Score (0 to 100) |
|---|---|---|
| Search scale | 20% | 21 |
| Search momentum | 20% | 33 |
How does Lilly (Eli) compare in Pharmaceuticals (S&P 500)?
| Rank | Brand | Dawn score |
|---|---|---|
| 1 | Johnson & Johnson | 55 |
| 2 | Bristol Myers Squibb | 51 |
| 3 | Pfizer | 49 |
| 4 | Zoetis | 48 |
| 5 | Viatris | 45 |
| 6 | Merck & Co. | 41 |
| 7 | Lilly (Eli) | 35 |
Where do the numbers come from?
Search figures are Google search estimates for the brand and its products. Site figures are third-party traffic estimates. A Dawn score measures attention, not revenue.